Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

ACADIA Pharmaceuticals Inc. (ACAD)

-NasdaqGM

14.19 Up 0.40(2.89%) 4:00PM EDT|After Hours : 14.34 Up 0.15 (1.06%) 6:04PM EDT

Add to Portfolio
ProfileGet Profile for:
ACADIA Pharmaceuticals Inc.
3911 Sorrento Valley Boulevard
San Diego, CA 92121
United States - Map
Phone: 858-558-2871
Fax: 858-558-2872
Website: http://www.acadia-pharm.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:26

Business Summary 

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer’s disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on ACADIA Pharmaceuticals Inc.

Key Executives 
 PayExercised
Dr. Uli Hacksell Ph.D., 63
Chief Exec. Officer, Pres and Director
823.00K6.00K
Mr. Thomas H. Aasen CPA, 52
Chief Financial Officer, Chief Bus. Officer, Principal Accounting Officer, Exec. VP and Treasurer
474.00K24.00K
Mr. Glenn F. Baity , 43
VP, Gen. Counsel, Corp. Compliance Officer and Sec.
412.00K0.00
Dr. Roger G. M. Mills M.D., 55
Chief Medical Officer and Exec. VP of Devel.
552.00K0.00
Ms. Lisa Barthelemy ,
Director of Investor Relations
N/AN/A
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders